Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BDX

STRONG BUYAPPROVE

Becton, Dickinson and Company · Healthcare · United States · $43.1B · Avg Vol: $384M/d

90
StockRank
Get insider-trade alerts
Q
57
V
66
M
66
P/E (TTM)
27.6x
ROE
6.7%
D/E
0.7x
Dividend %
2.6%
AI CONVICTION THESIS

Becton Dickinson clears the calibrated bar. All three legs are above the floor (Q56 V67 M60) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure on file is selling that rounds to 0.00% of shares outstanding, which the framework treats as unusable rather than adverse, and there is no negative earnings revision. Medical device demand is defensive, with a large recurring consumables base insulated from the squeezed-consumer theme.

COMPANY DESCRIPTION

Becton, Dickinson and Company (BD) is a global medical technology company developing, manufacturing, and selling medical devices, instrument systems, and reagents. BD is a market leader in critical healthcare segments like medication management, infection prevention, and diagnostic systems, supported by a vast intellectual property portfolio and global distribution. It is a highly diversified and essential supplier to the global healthcare industry, known for its broad product portfolio and significant installed base.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue18.9B19.4B20.2B21.8B5.0%22.2B19.2B19.7B-5.0%
EPS5.934.975.965.83-0.6%5.595.085.43-3.5%
Shares283.4M290.4M289.1M285.4M+0.7%275.5M
Debt16.1B15.9B20.1B19.2B6.1%17.3B
Equity25.3B25.8B25.9B25.4B0.1%
Op CF2.6B3.0B3.8B3.4B9.2%3.8B
Inv CF-3.2B-716.0M-5.5B-818.0M
Fin CF-591.0M-2.0B2.1B-3.6B
Loading 1Y...
PRICE (1Y)+8.7%
141146150155160Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$158.92
RSI (14)
53.8
52W High
$184.86
From 52W High
0.9%

SCORE BREAKDOWN

Quality
57
ROIC
5.3%58.9
ROE
6.7%62.6
GP/Assets
18.9%45.8
Op. Margin
14.7%75.6
FCF/Assets
8.2%81.5
Piotroski
783.4
Int. Cover
4.1x49.3
D/E Ratio
0.72x21.5
Current Ratio
0.94x9.6
Value
66
P/E (TTM)
27.6x42.8
EV/EBITDA
9.6x70.3
P/FCF
9.5x84.1
P/B
1.8x65.3
P/S
1.9x69.2
Div Yield
2.6%61.3
Momentum
66
52W High %
86%79.3
RS 6M
-6%65.6
SMA 50/200
0.98x59.2
EPS Rev 4W
+0.2%79.3
EPS Rev 12W
-0.7%49.2
EPS Improve
+140%82.0
Q Growth
N/A

FUNDAMENTALS

Market Cap
$43.1B
P/E (Forward)
11.5x
Gross Margin
47.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDX are excluded.

TickerCompanyMkt CapStockRankSignal
BDXBecton, Dickinson and Company(you)$43.1B90STRONG BUY
RMD.AXResMed Inc.$29.0B93STRONG BUY
WSTWest Pharmaceutical Services, Inc.$23.1B77BUY
ALGNAlign Technology, Inc.$12.0B93STRONG BUY
SOLVSolventum Corporation$13.5B80BUY
ISRGIntuitive Surgical, Inc.$120.9B66BUY
BAXBaxter International Inc.$11.6B71BUY
NVSTEnvista Holdings Corporation$4.3B90STRONG BUY
ATRAptarGroup, Inc.$8.4B74BUY
ICUIICU Medical, Inc.$3.9B83STRONG BUY

Peer medians: ROE -25.7% · P/E 27.9x · Gross margin 50.8%

Becton, Dickinson and Company (BDX) — Stock Score Summary

Becton, Dickinson and Company (BDX) has a MoatMap StockRank of 90/100 based on Quality (57/100), Value (66/100), and Momentum (66/100) factor scores. The current signal is STRONG BUY. Becton Dickinson clears the calibrated bar. All three legs are above the floor (Q56 V67 M60) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure on file is selling that rounds to 0.00% of shares outstanding, which the framework treats as unusable rather than adverse, and there is no negative earnings revision. Medical device demand is defensive, with a large recurring consumables base insulated from the squeezed-consumer theme.

Becton, Dickinson and Company (BD) is a global medical technology company developing, manufacturing, and selling medical devices, instrument systems, and reagents. BD is a market leader in critical healthcare segments like medication management, infection prevention, and diagnostic systems, supported by a vast intellectual property portfolio and global distribution. It is a highly diversified and essential supplier to the global healthcare industry, known for its broad product portfolio and significant installed base.

Key Financial Metrics

Price$158.92
Market Cap$43.1B
P/E (TTM)27.64
P/E (Forward)11.51
Price/Book1.76
Return on Equity6.7%
Return on Invested Capital5.3%
Debt/Equity0.72x
Gross Margin47.1%
Operating Margin14.7%
Revenue Growth5.2%
Dividend Yield2.6%
Free Cash Flow$4.5B

Becton, Dickinson and Company operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Becton, Dickinson and Company’s (BDX) StockRank?
MoatMap’s StockRank for Becton, Dickinson and Company (BDX) is 90/100, with a Strong Buy signal. It is a composite of Quality (57), Value (66), and Momentum (66) factor ranks across MoatMap’s 20,000+ stock universe.
Does Becton, Dickinson and Company have an economic moat?
Becton, Dickinson and Company (BDX) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Becton, Dickinson and Company a buy, hold, or sell?
MoatMap’s current signal for Becton, Dickinson and Company (BDX) is Strong Buy, based on a StockRank of 90/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Becton, Dickinson and Company in?
Becton, Dickinson and Company (BDX) operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry (United States).